A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Stopped early

Conditions studied: Mucopolysaccharidosis III-B

In brief

This is a multicenter, non-interventional, long-term follow-up (LTFU) study in participants who have been treated with ABO-101 in a prior trial. Eligible participants will undergo clinical evaluations at prespecified intervals for 3 years from the last visit in the prior clinical trial (up to 5 years post-treatment).

Key facts

Study ID

NCT04655911

Run by

Abeona Therapeutics, Inc

People needed

1

Starts

2020-10-28

Expected to finish

2022-04-07

Last updated by the study team

2022-05-31

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants that have completed a prior clinical trial involving the administration of ABO-101
• Parent(s)/legal guardian(s) of participant willing and able to complete the informed consent process and comply with study procedures and visit schedule

You may not qualify if…

• Planned or current participation in another clinical trial that may confound the safety and efficacy evaluation of ABO-101 during the duration of this study
• Any other situation that precludes the participant from undergoing procedures required in this study

Where it is running

• Nationwide Children's Hospital — Columbus, Ohio, United States
• Armand-Trousseau Hospital — Paris, France
• University Hospital Hamburg-Eppendorf — Hamburg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.